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We thank the Editors and the Reviewers for the time and efforts made to revise our 
manuscript. As suggested, we looked at the figures by the Reviewer #2. You can find 
below our response to the specific 5HYLHZHU¶Vrequests. 
 
 
 
Reviewer #2: General comments͒ . The authors revised their manuscript according to 
the reviewers' comments as much as possible. However, there is a minor concern 
regarding the definition. Is poorly cohesive carcinoma with intracytoplasmic lumen 
which mimics to true "signet ring" (Figure A, arrows) signet-ring cell carcinoma? In 
addition, can carcinoma cells consisting of a ubiquitous oval nuclei and relatively 
abundant mucus (Figure B, arrows) be called as signet-ring cell carcinoma? 
 
 
 
   
We deeply thank the Reviewer for this important comment. Indeed, the reason to 
make some consensus on morphology of SRC is to make better categories to study 
follow-up/ therapies etc. As for the definition of what we call a signet ring cell on an 
individual cell level, it would be very difficult to say until we have more detailled 
molecular data. Also, we think that one cannot decide on the % of SRCs of a tumour 
XVLQJKLJKSRZHUILJXUHV+RZHYHUWRPDNHDQDWWHPSWWRDQVZHUWRWKH5HYLHZHU¶V
specific requests:  
 
 
1) In figure A you can see these cells that have a big vacuole in the cytoplasm 
surrounded by a mor bubbly cytplasm and the nucleus on one side although 
not really squeezed to a signet ring shape. They are for sure not classical 
signet ring cells, as such this tumour (A) would fall in the category of PC 
<10% SRC.  
2) In figure B, at the right bottom you can just see what we would call a classical 
signet ring cell, while the neighbouring cells are likely signet ring cells in 
development. Indeed, we think that it takes some time to accumulate the mucin 
in the cytoplasm to squeeze the nucleus to the edge. This tumour (B) would fall 
in the category of poorly cohesive carcinoma with features of 10-90% signet 
ring cells. 
 
 
 
 
$XWKRUV
5HVSRQVHWR5HYLHZHUV
&RPPHQWV &OLFNKHUHWRGRZQORDG$XWKRUV
5HVSRQVHWR5HYLHZHUV
&RPPHQWVQG5HVSRQVHWR5HYLHZHUGRF[
August, 7th 2018 
 
Dear Editor,  
 
We appreciate your JournaO¶V LQWHUHVW LQ RXU PDQXVFULSW :H DUH DZDUH WKDW WKHUH DUH
some differences in the interpretation of gastric cancer morphology between the Eastern 
and Western pathologist. Indeed, one of the main reasons to make some consensus on 
morphology of SRC is to make better categories to study follow-up and therapies of 
these tumours also across world regions. I hope this further revision would satisfy the 
Editors and Reviewers requests. 
Please, ILQG HQFORVHG RXU UHVSRQVH WR WKH UHYLHZHUV¶ FRPPHQWV DQG WKH UHYLVHG
manuscript. Again, we appreciate your thoughtful consideration of our paper and we 
look forward to future correspondence. 
Best regards,͒  
 
Prof. Giovanni de Manzoni 
General and Upper GI Surgery Division  
University of Verona 
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ABSTRACT 
 
Background and aims: Clinicopathological characteristics of gastric cancer (GC) are changing, 
especially in the West with a decreasing incidence of distal, intestinal type tumours and a 
corresponding increasing proportion of tumours with Laurén diffuse or WHO poorly cohesive (PC) 
including signet ring cell (SRC) histology. In order to accurately assess the behavior and the 
prognosis of these GC subtypes, the standardization of pathological definitions is needed.  
Methods: A multidisciplinary expert team belonging to the European Chapter of International 
Gastric Cancer Association (IGCA) identified 11 topics on pathological classifications used for PC 
and SRC GC.  The topics were debated during a dedicated Workshop held in Verona in March 
2017. Then, through a Delphi method, consensus statements for each topic were elaborated. 
Results: A consensus was reached on the need to classify gastric carcinoma according to the most 
recent edition of the WHO classification which is currently WHO 2010. Moreover, in order to 
standardize the definition of SRC carcinomas, the proposal that only WHO PC carcinomas with 
more than 90% poorly cohesive cells having signet ring cell morphology have to be classified as 
SRC carcinomas was made. All other PC non-SRC types have to be further subdivided into PC 
carcinomas with SRC component (<90% but >10% SRCs) and PC carcinomas not otherwise 
specified  (<10% SRCs). 
Conclusion: The reported statements clarify some debated topics on pathological classifications 
used for PC and SRC GC. As such, this consensus classification would allow the generation of 
evidence on biological and prognostic differences between these GC subtypes. 
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INTRODUCTION 
 
Despite a declining incidence, Gastric Cancer (GC) is still one of the major causes of cancer 
death worldwide [1]. Evidence has accumulated over the last decades that clinicopathological 
characteristics of GC are changing, especially in the West [2-4] with a decreasing incidence of distal, 
intestinal type tumours and a corresponding increasing proportion of tumours with Laurén diffuse [5] 
or WHO [6] poorly cohesive (PC) including signet ring cell (SRC) histology [2-4].  
Conflicting data exist about the prognostic relevance of SRC histology [7-8]. While some authors 
report a relationship between SRC histology and poor prognosis [7], other studies have not 
confirmed this finding [8]. More recently, some comparative studies from Western and Asian authors 
[9, 10] suggested that the prognostic impact of SRC histology depends on the stage of the disease, 
being favourable in early stages but adverse in advanced tumour stages. One of the main reasons for 
these inconsistent findings over the relationship between SRC and prognosis appears to be a lack of 
standardization of GC histological subtype definitions. The 2010 WHO classification [6] defines PC 
tumours as GC composed of isolated or small groups of tumour cells. If neoplastic cells with SRC 
morphology predominate in the tumour, the tumour is defined as SRC carcinoma. In reality, the 
terms Laurén ³GLIIXVH W\SH´ ³SRRUO\ FRKHVLYH´ and ³VLJQHW ring FHOO´ GC are often used 
indiscriminately. As a consequence, tumours having major and minor SRC components may have 
been inappropriately considered together in comparative studies [11]. 
Standardization of terminology and classifications is a crucial step in order to accurately assess 
epidemiological trends and to allow prediction of prognosis and/or response to chemotherapy of GC 
patients with SRC as well as PC non-SRC tumours compared to other GC subtypes and to design 
tailored treatment strategies. In order to reach a consensus on the pathological classification of PC 
and SRC GC, a multidisciplinary  expert team belonging to the European Chapter of International 
Gastric Cancer Association (IGCA) attended a dedicated Workshop in Verona in March 2017.  
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METHODS 
 
The methodology of this project was similar to that of other multicentric consensus reports 
[12,13]
. After establishing the purpose of the project, a restricted working group (RWG) of the 
European Chapter of IGCA identified areas of uncertainty about the histopathological definitions 
and classifications of PC and SRC gastric cancers in order to define the topics for debate. 
Next, an expanded working group (EWG) of European experts (Table 1), was invited to 
take part in a dedicated workshop held in Verona, Italy, on the 17th of March, 2017. During the 
Workshop, the previoulsy identified topics were discussed and a draft statement in response to each 
topic was recorded. 
Each expert was asked to comment and suggest modifications to the draft statements 
through a Delphi method implementation. These suggestions were made available to the other 
experts in a series of web-based discussion rounds for further discussion and definitive approval. 
The grade of expert agreement to each statement is reported. 
 
RESULTS 
Consensus statements are reported as follows. There was unanimous agreement to each statement, 
except for the statement 5 where one of the experts disagreed.   
 
TOPIC 1 
What is the unequivocal definition of a signet ring cell (SRC)? 
STATEMENT 1  
The definition of a signet ring cell is that of a cell with ample cytoplasmic mucin which appears 
optically clear on Haematoxylin Eosin (HE) staining and an eccentrically placed nucleus [6]. All 
other poorly cohesive cancer cells that do not display this specific morphology should be classified 
as poorly cohesive cells (PC) not otherwise specified (NOS). 
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 TOPIC 2 
Is a cell with signet ring morphology always a malignant cell? What are the main differential 
diagnoses of cells with poorly cohesive/signet ring cell morphology? 
STATEMENT 2 
No, a cell with signet ring morphology is not always malignant. There are benign lookalikes that 
can mimic signet ring cell carcinoma which are illustrated in Panel Figure 1 and Figure 2 [14]. 
Furthermore, dystrophic goblet cells, non-neoplastic epithelial cells associated with ulceration and 
ischaemia, macrophages or mesothelial cells in cytology preparations can look like signet ring 
cells. 
Apart from benign signet ring cell change, lymphoma, poorly differentiated intestinal gastric 
adenocarcinoma, neuroendocrine tumours, metastatic lobular breast cancer, ovarian cancer and 
melanoma should be considered in the differential diagnosis of signet ring cell carcinoma. 
. 
TOPIC 3 
Can SRC carcinoma be identified by other means than HE morphology? Are there routinely 
used immunohistochemical (IHC) marker and if so, what are they? 
STATEMENT 3 
Currently there are no specific IHC markers used routinely. E-cadherin or cytokeratin subtyping do 
not aid in the identification of signet ring cells. However, histochemical staining for mucin (AB- 
PAS) can be used to confirm the presence of mucin in signet ring cells.  
 
TOPIC 4 
Currently, the terms ³GLIIXVH W\SH´ cancers according to Laurén classification, ³poorly 
cohesive FDUFLQRPDV´ according to the WHO classification 2010, ³signet ring cHOO´ 
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carcinomas, and ³OLQLWLV SODVWLFD´ are used indiscriminately. How can terminology used to 
describe the histology of these tumours be standardized?  
STATEMENT 4  
In the pathology report, gastric adenocarcinoma should be classified according to the most recent 
edition of the WHO classification which is currently the 4th ed published in 2010 [6]. The Laurén 
³GLIIXVH´ type [5] corresponds to the WHO category of ³poorly cRKHVLYH´ carcinomas.  
The WHO 2010 category of PC carcinoma includes SRC which is defined as PC carcinoma that 
contains predominantly or exclusively signet ring cells (See Statement 5). 
The term ³OLQLWLV SODVWLFD´ should only be used for the description of the macroscopic 
characteristics of the tumour. 
 
TOPIC 5 
A SRC carcinoma is defined according to the WHO as PC carcinoma containing 
predominantly or exclusively signet ring cells. Should an internationally standardized method 
be used, to define the proportion of signet ring cells required to subclassify tumours with 
signet ring cells?  
STATEMENT 5 
In order to standardize the definition of SRC cancers, we propose that only WHO PC carcinomas 
with more than 90% poorly cohesive cells having classical signet ring cell morphology should be 
classified as SRC carcinomas. 
We propose to use the following subclassification of PC and SRC carcinomas:  
- Signet ring cell (SRC) type (>90% of signet ring cells) 
- Combined poorly cohesive NOS and SRC Carcinoma (PC-NOS/SRC; <90% 
but >10% of signet ring cells) 
- Poorly cohesive NOS (PC-NOS; <10% of signet ring cells) 
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We believe that by using the above categories of poorly cohesive carcinomas, and comparing 
tumours with almost exclusive (>90%) signet ring cells to those with lower (<90% but >10% and 
<10%) proportion of signet ring cells in retrospective and prospective studies, the prognostic 
differences of PC tumours with different proportion of cells with signet ring morphology can be 
accurately investigated. 
It is important that these categories/subclassification are only used for PC and SRC carcinomas. 
Mucinous cancers are characterized by the presence of extracellular mucin in more than 50% of 
the tumour area. Even if mucinous cancers contain signet ring cells, they should not be classified as 
poorly cohesive/signet ring cell carcinomas as mucinous cancers have different biology and 
prognosis.  
 
TOPIC 6 
How big is the discrepancy between histological tumour type in endoscopic biopsies and 
resected specimen in gastric cancer using the current WHO classification? Do you believe that 
this discrepancy is larger for PC / SRC carcinomas? 
STATEMENT 6 
Due to the uncertainty about the definition used when reporting results, it is currently unclear 
whether there is a discrepancy between biopsy classification and resection specimen classification. 
We therefore believe that it is necessary to report in PC carcinoma whether signet ring cells are 
present in specimens or not. The concordance between preoperative biopsies and resected 
specimens according to the proposed definitions (statement 5) should be assessed. 
 
TOPIC 7 
Is the determination of the pathological depth of invasion (pT category) in PC/SRC 
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carcinomas, in particular regarding the involvement of the serosa, more difficult than in other 
histological types of gastric cancer? 
STATEMENT 7 
There are more difficulties in determining the pathological T category in PC and SRC carcinomas. 
Immunohistochemical staining for cytokeratin does not help as the mesothelial cells of the serosa 
also express cytokeratins. Elastica stains may be helpful to identify the location of the serosa. 
 
TOPIC 8 
Is the type of stroma reaction the same in all SRC cancers? If not, do you think this could 
have a prognostic impact? 
STATEMENT 8 
The stroma reaction is not the same in all PC and SRC carcinomas. The stroma reaction may 
change depending on depth of tumour invasion. It is likely that the type of stroma reaction has a 
prognostic impact, but available data are limited [15]. 
 
TOPIC 9 
Does neoadjuvant treatment modify gastric cancer histopathological phenotype? Can a 
histopathological response to neoadjuvant chemotherapy (tumour regression grade) be 
established in SRC carcinomas in the same way as in non-SRC carcinomas? Are there specific 
pathological criteria to assess the response to neo-adjuvant treatments in SRC cancers 
carcinoma? 
STATEMENT 9 
Apart from seeing regressive features like fibrosis and necrosis, there is no definitive evidence that 
the histological phenotype of cancer cells change after neoadjuvant chemotherapy. 
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In GC patients who received neoadjuvant therapy, we only have the pretreatment diagnostic biopsy 
to determine the tumour phenotype. There is no evidence yet that the tumour phenotype changes 
after chemo(radio)therapy. By reviewing slides of resected specimens from clinical trials 
comparing surgery alone to neoadjuvant therapy followed by surgery, we could evaluate the impact 
of neoadjuvant therapy on the histological tumour phenotype in gastric adenocarcinoma including 
in tumours with PC/SRC histology classified on the pretreatment  diagnostic biopsies. 
At the moment, there are no specific pathologic criteria to assess the response to neoadjuvant 
treatment in poorly cohesive and signet ring cell types.  
Tumour regression grade according to Becker [16] or Mandard [17] is currently reported in 
pathological reports in most Western countries. It is noteworthy that pathologists have difficulties 
in particular in PC GC in differentiating treatment naïve desmoplastic stroma from treatment 
induced fibrosis. It therefore appears necessary to develop specific pathologic regression systems 
for PC and SRC tumours. 
Of note, these pathologic regression systems should include not only regression grading for the 
primary tumour but also for the lymph nodes. Indeed, for oesophageal and cardia cancer [18-24] the 
prognostic relevance of nodal response to preoperative treatments has already been demonstrated, 
and this is likely to be significant in gastric cancer, too. 
It would be very interesting to evaluate the rates of pathologic tumour and nodal response to 
preoperative treatment according to the proportion of signet ring cells, i.e. based on the 
classification proposed in Statement 5. 
 
TOPIC 10 
Is it possible to find signet ring cells also in the context of tubular or papillary gastric 
adenocarcinoma? If yes, how do you classify this tumour? 
STATEMENT 10 
The WHO classification 4th ed. [6] defines µmixed adenocarcinoma¶DV a tumor with a 
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discrete component of tubulo-papillar and a poorly cohesive-SRC component. It 
means that each component should be clearly separate. There is currently no cut-off 
defined with respect to percentage of each component for a tumour to be classified 
as mixed adenocarcinoma. However, if only rare signet ring cells/rare poorly 
cohesive cells are present, for example at the invasive edge, the tumour should still 
be classified as tubular or papillary tumour. 
 
 
 
TOPIC 11 
 In case of WHO mixed type gastric cancers, is there pathological evidence that the PC/SRC 
component is more µDJJUHVVLYH¶ showing a higher frequency of lymph node metastases?  
STATEMENT 11 
Both, the tubulo-papillary and PC-SRC components may be aggressive.  
The two components have different pathways of tumour dissemination with the tubulo-papillary 
(Laurén: intestinal type) component spreading more frequently by angioinvasion, while the PC-
SRC (Laurén: diffuse type) component tend to metastasise to the peritoneum [25]. 
Currently, one can only speculate that the cumulative effect of the adverse behaviours of intestinal 
and diffuse type gastric carcinoma is responsible for the greater biological aggressiveness of mixed 
type gastric carcinoma compared to ³SXUH´ intestinal and diffuse gastric carcinoma [26-33]. The 
level of existing evidence is too low for a definitive conclusion. 
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DISCUSSION 
 
The proportion of Laurén diffuse and WHO PC and SRC gastric cancer subtypes have 
increased in recent years, especially in the West [2-4]. Some studies reported an independent 
unfavourable prognostic impact of SRC histology compared to other histotypes [7], while others 
could not confirm this [8]. More recently a stage-dependent prognostic role of SRC has been 
suggested by Western and Eastern authors [9,10]. Different proportions of early and advanced SRC 
tumours in the published series may have caused the inconsistency of data reported so far.  
Most importantly, there is no standardization in the terminology used to define tumours with 
signet ring cells and very often the definitions of ³GLIIXVH W\SH´ cancers according to Laurén 
classification, ³poorly cohesive ´ and ³signet ring cHOO´ gastric carcinomas according to the 2010 
WHO classification, or ³OLQLWLV SODVWLFD´ are used indiscriminately. Findings reported in comparative 
studies [7-10] could have been affected by the heterogeneity of SRC and non-SRC cancers. To 
establish reproducible definitions towards standardised classification of gastric cancer, a European 
consensus group has produced the definitions described in this paper.  
The two key issues for pathologists are firstly, that gastric carcinoma should be classified according 
to the most recent edition of the WHO classification which is currently WHO 2010 [6]. The Laurén 
³GLIIXVH´ type corresponds to the WHO category of ³poorly cohesive´ carcinomas.  
Secondly, in order to standardize the definition of SRC carcinomas, we propose that only WHO PC 
carcinomas with more than 90% poorly cohesive cells having signet ring cell morphology should be 
classified as SRC carcinomas. All other PC non-SRC types should be further subdivided into PC 
carcinomas with SRC component (<90% but >10% signet ring cells) and PC carcinomas NOS  
(<10% signet ring cells). This classification reflects the hypothesis that the extent of SRCs may 
represent a differentiation grade in PC and SRC carcinomas. Studies in Hereditary Diffuse Gastric 
Cancer (HDGC) suggest that intramucosal lesions morphologically characterized by typical signet 
ring cells without expression of Ki67 and p53 represent an ³LQGROHQW´ phenotype. By contrast 
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advanced carcinomas that display an ³DJJUHVVLYH´ phenotype with positive immunoreaction for 
Ki67 and p53, are composed of poorly cohesive pleomorphic cells without SRC morphology [34]. A 
recent study in Korean patients with gastric PC carcinoma subclassified each tumour on the basis of 
the prevalent histopathological component into ³SXUH´ SRC type (signet ring cells > 95%), ³SXUH´ 
PC not otherwise specified (PCC-NOS) type (i.e. no SRC), mixed SRC-predominant type (SRC > 
PCC-NOS, SRC >50%) or mixed PCC-NOS-predominant type (PCC-NOS >SRC) [35]. A distinct 
mutation pattern and significant differences in overall survival were reported for ³SXUH´ SRC type 
and ³SXUH´ PC not otherwise specified type, with better outcome for the former category. These 
findings support our proposal to distinguish different subcategories of PC gastric carcinoma. Such 
classification would allow the generation of evidence on biological and prognostic differences of 
these tumours according to the proportion of signet ring cells. 
In the Japanese pathological classification [36], the poorly differentiated non-solid type (por2) 
category that substantially corresponds to the WHO category of PC non-SRC type, is considered 
separately from the SRC type (Table 2). Also, in recent papers, Japanese authors [37] confirm that 
histopathological features of signet ring cell types differ from those of poorly differentiated (por2) 
tumours and highlight the need to differentiate them in clinical studies.   
It is important that pathologists attempt to subclassify gastric cancer on biopsies (when 
adequate biopsies are available) and not use the term µDGHQRFDUFLQRPD 126¶ since most patients 
will receive preoperative treatment which may change tumour morphology. Future clinical and 
translational research should include the creation of specific pathologic regression systems for 
tumours with PC/SRC, but also a more in-depth analysis of role of stroma reaction and genomic 
characteristics of these subtypes of gastric cancer. 
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Figures Legend 
Panel Figure 1: Mimickers of signet ring cell carcinoma in gastric mucosa 
A ±  Vacuolization of the foveolar epithelium; B ±  Hyperplastic polyp with globoid change; C ± 
Glassy cell change; D ± prominent mucous neck cells; E ±  Ischemic/ autolytic change with loss of 
epithelial cells and signet cell change in a hyperplastic polyp; F ± Neuroendocrine tumor; G ± Low 
grade dysplasia and dystrophic intestinal metaplasia; H ± Xanthoma (H&E, original magnifications 
200-400x). 
 
Figure 2 Carcinoma-like signet ring cells in MALT lymphoma: multiple single and clusters of 
SRCs characterized by abundant pale cytoplasm and a small peripheral nucleus, intermingled with 
diffuse infiltrate of marginal-zone B cells. 
 
Panel Figure 2: Poorly cohoesive gastric carcinoma, examples of morphology 
A ± Signet ring cell carcinoma (SRCC) (>90% of signet ring cells): classical signet ring cells are 
seen at the superficial layer of gastric mucosa ; B ± Combined PCC-NOS and SRCC (PCC-NOS/ 
SRC) (<90% but >10% of signet ring cells): this case has two components, the superficial part is 
composed of classical signet ring cells and the deeper part is composed by poorly cohesive, non-
signet ring cells; C ± Combined PCC-NOS and SRCC (PCC-NOS/ SRC) (<90% but >10% of 
Signet Ring cells): in this case, the two cell types (signet ring and poorly cohesive cells) are 
intermingled; D ± Poorly cohesive carcinoma NOS (PCC-NOS) (<10% of signet ring cells): the 
poorly cohesive, non-signet ring cells, are invading the muscle layer (H&E, original magnifications 
200-400x). 
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Table 1: List of participants at the Verona Workshop on Poorly Cohesive and Signet Ring Cell 
Gastric Cancer. 
NAME COUNTRY SPECIALITY 
Allum William United Kingdom Surgeon 
Baiocchi Gian Luca Italy  Surgeon 
Carneiro Fatima Portugal Pathologist 
De Manzoni Giovanni Italy Surgeon 
Flejou Jean-Francois France Pathologist 
Fumagalli Uberto Italy Surgeon 
Grabsch Heike Netherlands Pathologist 
Hoelscher Arnulf Germany Surgeon 
Iglesias Mar Spain Pathologist 
Mariette Christophe France Surgeon 
Marrelli Daniele Italy Surgeon 
Moenig Stefan Switzerland Surgeon 
Morgagni Paolo Italy Surgeon 
Pera Manuel Spain Surgeon 
Piessen Guillaume France Surgeon 
Reim Daniel Germany Surgeon 
Renaud Florence France Pathologist 
Roviello Franco Italy Surgeon 
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Saragoni Luca Italy Pathologist 
Scarpa Aldo Italy Pathologist 
Schneider Paul Switzerland Surgeon 
Tomezzoli Anna Italy Pathologist 
Vanderpost Chella Netherlands Pathologist 
Vieth Michael Germany Pathologist 
Wotherspoon Andrew United Kingdom Pathologist 
Zamboni Giuseppe Italy Pathologist 
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Table 2 Ȃ Comparison of different classifications of gastric cancer (Laurén, Nakamura, WHO and Japanese classifications) 
Laurén 
(1965) 
Nakamura 
(1968) 
WHO 
(2010) 
Japanese classification 
(2017) 
Intestinal Differentiated Common type: Papillary 
Tubular 
Common type: Papillary: pap 
Tubular 1 (well-differentiated): tub1 
Tubular 2 (moderately-differentiated): 
tub2 
Intestinal/diff
use 
Differentiated/ 
Undifferentiated 
Common type: Mucinous Common type: Mucinous 
Diffuse Undifferentiated  Common type: Poorly cohesive, SRC phenotype 
Poorly cohesive, other cell types 
Common type: SRC carcinoma: sig 
Poorly 2 (non-solid type): por2 
Mixed Undifferentiated Common type: Mixed  Description according to the proportion 
(e.g. por2>sig>tub2) 
Indeterminate Undifferentiated Common type: 
 
Special type: 
Poorly differentiated tubular (solid) 
carcinoma 
Undifferentiated carcinoma 
Common type: 
 
Special type: 
Poorly 1 (solid type): por1 
 
Undifferentiated carcinoma 
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 MINIABSTRACT 
This Consensus clarifies some debated topics on pathological classifications used for Poorly 
Cohesive and Signet Ring Cell Gastric Cancer. As such, it would allow the generation of strong 
evidences on biological and prognostic differences of these GC subtypes. 
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